Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (26767)	12/6/1998 9:23:00 PM
From: Henry Niman	Respond to of 32384

The "Bottle Report" doesn't cover those two specifically, but under "Trade Talk" they say: "Our trade sources have indicated that demand for SGP/COR's(CORR-12) Integrelin and MRK's Aggrastat, IIb/IIIa inhibitors, have picked up of late. Demand appeared to be slow for both products through October, but through mid-November sales have risen significantly. It remains to be seen if this is an anomaly or not."

To: aknahow who wrote (26767)	12/6/1998 9:37:00 PM
From: Henry Niman	Respond to of 32384

The prior week had a bit more info (but not a weekly table). Under Trade Talk: "COR (CORR-10) is now predicting 1998 sales of $10 million for Integrilin, a IIb/IIIa antiplatelet agent. In 3Q98 COR reported that SGP booked $2.3 M in sales of Integrilin, and $3.7 launch through September 30, 1998. Merck's Aggrestat only had sales 0f $5M in 3Q98, while Centocor/Lilly's (CNTO-49) ReoPro maintains a dominant position with 3Q98 sales of $87M. Integrilin and Aggrastat are being compared to each other for they are both indicated for unstable angina (UA), whereas ReoPro is only indicated for coronary syndromes related to angioplasty. Integrilin is also indicated for acute coronary syndromes related to angioplasty, although Aggrastar is not. In addition to both indications, COR/SGP have instituted aggressive pricing where Integrilin only costs $173 for a course of angioplasty therapy compared to Reopro's cost of around $1350. We maintain our belief that ReoPro will continue to be the gold standard....."